Health Advisory

Authorization of Paxlovid and Molnupiravir for Oral Treatment of Mild-to-Moderate COVID-19

January 10, 2022

The following information is issued on behalf of the SF COVID Task Force

In late December 2021, FDA authorized two new, oral antiviral medications for the early treatment of outpatients with mild-to-moderate COVID-19 who are at high risk for progression to severe disease. The California Department of Public Health (CDPH) has issued health advisories with information and guidance on use of both Paxlovid (Ritonavir-boosted Nirmatrelvir) and Molnupiravir.

Supply of these products is currently extremely limited and available only through a few designated pharmacies. CDPH has issued clinical criteria in a Provider Letter to prioritize the doses that are available.

San Francisco Department of Public Health is committed to ensuring ethical distribution of this scarce resource. Using a data-driven, equitable, and transparent process, healthcare systems in San Francisco anticipate and request the amount of drug anticipated to be needed, and doses are then allocated by CDPH to the extent that supply is available.

As the manufacturing of these therapeutic agents ramps up over the next several months and many more treatment courses become available, SFDPH will work to expand pharmacy access to additional locations, including more community-based pharmacies.

Documents related to these COVID-19 oral therapeutic agents are posted at www.sfcdcp.org/COVID-19-therapeutics/ and will be updated as new information becomes available.

Additional Resources

SFDPH COVID-19 information for SF healthcare providers

CDC alert on COVID-19 therapeutics

NIH statement on therapies for high-risk, non-hospitalized patients